Trial Profile
An Open-Label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2010
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Diabetic nephropathies; Glomerulonephritis
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 17 Jun 2009 New trial record